

Processing your request...
Dialog Index Results

Your select statement is 'S SCPA49' in databases ALLMEDPH.

☒ Select All ☒ Clear Selections

<u>File</u>	<u>Database Name</u>	<u>Hits</u>
<input type="checkbox"/> 5:	<u>BIOSIS Previews® (1969-present)</u>	6
<input type="checkbox"/> 16:	<u>Gale Group PROMT® (1990 - present)</u>	2
<input type="checkbox"/> 34:	<u>SciSearch® - a Cited Reference Science Database - 1990-</u>	5
<input type="checkbox"/> 71:	<u>Elsevier Biobase</u>	5
<input type="checkbox"/> 73:	<u>EMBASE® (1974-present)</u>	5
<input type="checkbox"/> 98:	<u>General Science Abstracts/Fulltext</u>	1
<input type="checkbox"/> 135:	<u>NewsRX Weekly Reports</u>	2
<input type="checkbox"/> 144:	<u>PASCAL</u>	4
<input type="checkbox"/> 155:	<u>MEDLINE® (1966-present)</u>	5
<input type="checkbox"/> 156:	<u>TOXFILE</u>	1
<input type="checkbox"/> 340:	<u>CLAIMS®/U.S. Patents</u>	2
<input type="checkbox"/> 349:	<u>WIPO/PCT Patents Fulltext</u>	2
<input type="checkbox"/> 399:	<u>CA SEARCH® - Chemical Abstracts® (1967-present)</u>	2
<input type="checkbox"/> 440:	<u>Current Contents Search®</u>	5
<input type="checkbox"/> 636:	<u>Gale Group Newsletter Database(TM)</u>	2
<input type="checkbox"/> 654:	<u>U.S. Patents Fulltext (1976-present)</u>	4

There are 16 databases matching your statement 'S SCPA49'.

☒ Select All ☒ Clear Selections

2/3,AB/1 (Item 1 from file: 5)

0012560364 Biosis No.: 200000278677

Characterization of the streptococcal C5a peptidase using a C5a-green fluorescent protein fusion protein substrate

Author: Stafslien D K; Cleary P P (Reprint)

Author Address: Department of Microbiology, University of Minnesota, 420 Delaware St., S.E., Minneapolis, MN, 55455, USA**USA

Journal: Journal of Bacteriology 182 (11): p 3254-3258 June, 2000 2000

Medium: print

ISSN: 0021-9193

Document Type: Article

Record Type: Abstract

Language: English

Abstract: A glutathione-S-transferase (GST)-C5a-green fluorescent protein (GFP) fusion protein was designed for use as a substrate for the streptococcal C5a peptidase (SCPA). The substrate was immobilized on a glutathione-Sepharose affinity matrix and used to measure wild-type SCPA activity in the range of 0.8 to 800 nM. The results of the assay demonstrated that SCPA is highly heat stable and has optimal activity on the synthetic substrate at or above pH 8.0. SCPA activity was unaffected by 0.1 to 10 mM Ca²⁺, Mg²⁺, and Mn²⁺ but was inhibited by the same concentrations of Zn²⁺. The assay shows high sensitivity to ionic strength; NaCl inhibits SCPA cleavage of GST-C5a-GFP in a dose-dependent manner. Based on previously published computer homology modeling, four substitutions were introduced into the putative active site of SCPA: Asp130-Ala, His193-Ala, Asn295-Ala, and Ser512-Ala. All four mutant proteins had over 1,000-fold less proteolytic activity on C5a in vitro, as determined both by the GFP assay described here and by a polymorphonuclear cell adherence assay. In addition, recombinant SCPA1 and SCPA49, from two distinct lineages of *Streptococcus pyogenes* (group A streptococci), and recombinant SCPB, from *Streptococcus agalactiae* (group B streptococci), were compared in the GFP assay. The three enzymes had similar activities, all cleaving approximately 6 mol of C5a mmol of SCP-1 liter⁻¹ min⁻¹.

Biosis Previews(R) (Dialog® File 5): (c) 2004 BIOSIS. All rights reserved.

2/3,AB/2 (Item 2 from file: 5)

0011716037 Biosis No.: 199800510284

Impact of M49, Mrp, Enn, and C5a peptidase proteins on colonization of the mouse oral mucosa by *Streptococcus pyogenes*

Author: Ji Yinduo; Schnitzler Norbert; Demaster Eric; Cleary Patrick (Reprint)

Author Address: Box 196 FUMC, Dep. Microbiol., Univ. Minnesota, Minneapolis, MN 55455, USA **USA

Journal: Infection and Immunity 66 (11): p 5399-5405 Nov., 1998 1998

Medium: print

ISSN: 0019-9567

Document Type: Article

Record Type: Abstract

Language: English

Abstract: Resistance to phagocytosis is a hallmark of virulent *Streptococcus pyogenes* (group A streptococcus). Surface-bound C5a peptidase reduces recruitment of phagocytes to the site of infection, and hyaluronic acid capsules and/or the M protein limit the uptake of streptococci. In this study the relative impact of M and M-like proteins and the C5a peptidase on the virulence of a serotype M49 strain was assessed. The capacities of isogenic strains with an insertion mutation in emm49; with a deletion mutation in scpA49 (C5a peptidase gene); and with a deletion that removes all three M-like genes, mrp49, emm49, and enn49, to colonize mice and resist phagocytosis were compared. Experiments confirmed results obtained in an earlier study, which showed that the M49 protein was not required for in vitro resistance to phagocytosis, and also showed that the M protein was not required for colonization of mice. Failure to produce all three M-like proteins, M49, Mrp, and Enn49, significantly reduced the ability of these streptococci to resist phagocytosis in vitro but did not significantly alter the persistence of streptococci on the oral mucosa. In vitro experiments indicate that M+ streptococci are phagocytized by polymorphonuclear leukocytes that have been activated with phorbol-12-myristate 13-acetate or recombinant human C5a. This observation may explain the finding that expression of M49 protein is not essential for short-term colonization of the mouse oral mucosa.

Biosis Previews(R) (Dialog® File 5): (c) 2004 BIOSIS. All rights reserved.

2/3,AB/3 (Item 3 from file: 5)

0011621348 Biosis No.: 199800415595

Site directed mutagenesis of the streptococcal C5a peptidase

Author: Stafslien Deborah K; Cleary P Patrick

Author Address: Univ. Minnesota, Minneapolis, MN, USA**USA

Journal: Abstracts of the General Meeting of the American Society for Microbiology
98 p 59 1998 1998

Medium: print

Conference/Meeting: 98th General Meeting of the American Society for Microbiology
Atlanta, Georgia, USA May 17-21, 1998; 19980517

Sponsor: American Society for Microbiology

ISSN: 1060-2011

Document Type: Meeting; Meeting Abstract; Meeting Poster

Record Type: Citation

Language: English

Biosis Previews(R) (Dialog® File 5): (c) 2004 BIOSIS. All rights reserved.

2/3,AB/4 (Item 4 from file: 5)

0010961448 Biosis No.: 199799595508

Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus

Author: Ji Yinduo; Carlson Brian; Kondagunt Aparna; Cleary P Patrick (Reprint)

Author Address: Box 196 UMHC, Dep. Microbiol., Univ. Minnesota, Minneapolis, MN
55455, USA **USA

Journal: Infection and Immunity 65 (6): p 2080-2087 1997 1997

ISSN: 0019-9567

Document Type: Article

Record Type: Abstract

Language: English

Abstract: Early inflammatory events are initiated by phased production of C5a and interleukin-8 in tissue. Most serotypes of group A streptococci express a surface-bound peptidase (SCPA) which specifically cleaves mouse and human C5a chemotaxins. This study investigates the impact of SCPA on colonization of the nasopharyngeal mucosa of mice and evaluates its potential to induce protective immunity. Two strains, serotypes M6 and M49, which contain insertion and deletion mutations in the SCPA gene (scpA)

and represent the two major subdivisions of group A streptococci, were characterized and compared in a mouse intranasal infection model. In this model, SCPA mutants were more rapidly cleared from the nasopharynxes of inoculated mice compared with wild-type strains. A 2,908-bp fragment of scpA49 gene, obtained by PCR, was ligated to the expression vector pGEX-4T-1 and expressed in Escherichia coli. The affinity-purified DELTA-SCPA49 protein proved to be highly immunogenic in mice and rabbits. Although the purified DELTA-SCPA49 immunogen lacked enzymatic activity, it induced high titers of rabbit antibodies which were able to neutralize peptidase activity associated with M1, M6, M12, and M49 streptococci in vitro. This result confirmed that antipeptidase antibodies lack serotype specificity. Intranasal immunization of mice with the deleted form of the SCPA49 protein stimulated significant levels of specific salivary secretory immunoglobulin A (IgA) and serum IgG antibodies and reduced the potential of wild-type M1, M2, M6, M11, and M49 streptococci to colonize. These experiments suggest a new approach to vaccine development for prevention of streptococcal pharyngitis.

Biosis Previews(R) (Dialog® File 5): (c) 2004 BIOSIS. All rights reserved.

2/3,AB/5 (Item 5 from file: 5)

0010454976 Biosis No.: 199699089036

Conservation of the C5a peptidase genes in group A and B streptococci

Author: Chmouryguina Ilona; Suvorov Alexander; Ferrieri Patricia; Cleary P Patrick (Reprint)

Author Address: Dep. Microbiol., Box 196 UMHC, Univ. Minnesota, Minneapolis, MN 55455, USA **USA

Journal: Infection and Immunity 64 (7): p 2387-2390 1996 1996

ISSN: 0019-9567

Document Type: Article

Record Type: Abstract

Language: English

Abstract: The chromosome of group B streptococci (GBS) contains a gene which is related to the C5a peptidase gene (scpA) of group A streptococci (GAS). scpA encodes a surface-associated peptidase (group A streptococcal C5a peptidase (SCPA)) which specifically cleaves C5a, a major chemoattractant generated in serum by activation of complement. The entire scpA-like gene (scpB) was cloned from a GBS strain and sequenced. The gene encodes an open reading frame of 3,450 bp, which corresponds to a deduced protein (SCPB) of 1,150 amino acids with a molecular weight of 126,237 Da.

deduced protein (SCP_B) of 1,150 amino acids with a molecular weight of 126,237 Da. Nucleotide and deduced amino acid sequences of SCP_B were found to be highly homologous to those of SCP_As from GAS. Unexpectedly, scpA12 is more similar to scpB than to another GAS gene, scpA49. The sequence 5' of the open reading frame, including transcription start and a termination site in the signal sequence, is also similar to that of scpA, although less conserved than the coding sequences. The near identity of GBS and GAS peptidases is consistent with horizontal transmission of the scp gene between these species. Recombinant SCP_B was "pressed" in *Escherichia coli* by using the expression vector plasmid pGEX-4T-1 and was shown to be identical in size to the enzyme extracted from the parental GBS strain 78-471.

Biosis Previews(R) (Dialog® File 5): (c) 2004 BIOSIS. All rights reserved.

2/3,AB/6 (Item 6 from file: 5)

0009623908 Biosis No.: 199598091741

The group A streptococcal virR49 gene controls expression of four structural vir regulon genes

Author: Podbielski Andreas (Reprint); Flosdorff Annegret; Weber-Heynemann Josephine

Author Address: Inst. Med. Microbiol., Technical Univ., Pauwelsstr. 30, 52057 Aachen, Germany**Germany

Journal: Infection and Immunity 63 (1): p 9-20 1995 1995

ISSN: 0019-9567

Document Type: Article

Record Type: Abstract

Language: English

Abstract: Within a genomic locus termed the vir regulon, virR genes of opacity factor-nonproducing (OF-) group A streptococci (GAS) are known to control the expression of the genes encoding M protein (emm) and C5a peptidase (scpA) and of virR itself. Within the corresponding genomic locus, opacity factor-producing (OF+) GAS harbor additional emm-related genes encoding immunoglobulin G- and immunoglobulin A-binding proteins (fcrA and enn, respectively). The virR gene region of the OF+ GAS M-type 49 strain CS101 was amplified by PCR, and 2,650 bp were directly sequenced. An open reading frame of 1,599 bp exhibited 76% overall homology to published virR sequences. By utilizing mRNA analysis, the 5' ends of two specific transcripts were mapped 370 and 174 bp upstream of the start codon of this open reading frame. The deduced sequences of the corresponding promoters and their locations differed from

deduced sequences of the corresponding promoters and their locations differed from those of previously reported virR promoters. Transcripts from wild-type fcrA49, emm49, enn49, and scpA49 genes located downstream of virR49 were characterized as being monocistronic. The transcripts were quantified and mapped for their 5' ends. Subsequently, the virR49 gene was inactivated by specific insertion of a nonreplicative pSF152 vector containing recombinant virR49 sequences. The RNA from the resulting vir-mut strain did not contain transcripts of virR49, fcrA49, emm49, or enn49 and contained reduced amounts of the scpA49 transcript when compared with wild-type RNA. The mRNA control from the streptokinase gene was demonstrated not to be affected. When strain vir-mut was rotated in human blood, it was found to be fully sensitive to phagocytosis by human leukocytes. Thus, the present study provides evidence that virR genes in OF+ GAS could be involved in the control of up to five vir regulon genes, and their unaffected regulatory activity is associated with features postulated as crucial for GAS virulence.

Biosis Previews(R) (Dialog® File 5): (c) 2004 BIOSIS. All rights reserved.

2/3,AB/7 (Item 1 from file: 16)

05139291 Supplier Number: 47845096

Streptococcal Pharyngitis "Intranasal Immunization with C5a Peptidase Prevents Nasopharyngeal Colonization of Mice by the Group A Streptococcus."

Vaccine Weekly , p N/A

July 21 , 1997

Language: English **Record Type:** Fulltext

Document Type: Newsletter ; Trade

Word Count: 315

Gale Group PROMT(R) (Dialog® File 16): (c) 2004 The Gale Group. All rights reserved.

2/3,AB/8 (Item 2 from file: 16)
04643040 Supplier Number: 46830675

Conference Coverage (ICAAC) New Target for Strep Vaccines

Vaccine Weekly , p N/A

Oct 28 , 1996

Language: English **Record Type:** Fulltext

Document Type: Newsletter ; Trade

Word Count: 310

Gale Group PROMT(R) (Dialog® File 16): (c) 2004 The Gale Group. All rights reserved.

2/3,AB/9 (Item 1 from file: 34)

04932884 **Genuine Article#:** UT657 **Number of References:** 23

CONSERVATION OF THE C5A PEPTIDASE GENES IN GROUP-A AND GROUP-B STREPTOCOCCI

Author: CHMOURYGUINA I; SUVOROV A; FERRIERI P; CLEARY PP

Corporate Source: UNIV MINNESOTA,DEPT MICROBIOL,BOX 196

UMHC/MINNEAPOLIS//MN/55455; UNIV MINNESOTA,DEPT

MICROBIOL/MINNEAPOLIS//MN/55455; UNIV MINNESOTA,DEPT PEDIAT,DEPT
PATHOL & LAB MED/MINNEAPOLIS//MN/55455; RUSSIAN ACAD MED SCI,INST
EXPTL MED/ST PETERSBURG P22//RUSSIA/

Journal: INFECTION AND IMMUNITY , 1996 ; V 64 , N7 (JUL) , P 2387-2390

ISSN: 0019-9567

Language: ENGLISH **Document Type:** ARTICLE

Abstract: The chromosome of group B streptococci (GBS) contains a gene which is related to the C5a peptidase gene (scpA) of group A streptococci (GAS). scpA encodes a surface-associated peptidase (group A streptococcal C5a peptidase [SCPA]) which specifically cleaves C5a, a major chemoattractant generated in serum by activation of complement. The entire scpA-like gene (scpB) was cloned from a GBS strain and sequenced. The gene encodes an open reading frame of 3,450 bp, which corresponds to a deduced protein (SCPB) of 1,150 amino acids with a molecular weight of 126,237 Da. Nucleotide and deduced amino acid sequences of SCPB were found to be highly homologous to those of SCPAs from GAS. Unexpectedly, scpA12 is more similar to scpB than to another GAS gene, scpA49. The sequence 5' of the open reading frame, including transcription start and a termination site in the signal sequence, is also similar to that of scpA, although less conserved than the coding sequences. The near identity of GBS and GAS peptidases is consistent with horizontal transmission of the scp gene

between these species. Recombinant SCPB was expressed in *Escherichia coli* by using the expression vector plasmid pGEX-4T-1 and was shown to be identical in size to the enzyme extracted from the parental GBS strain 78-471.

SciSearch(R) Cited Ref Sci (Dialog® File 34): (c) 2004 Inst for Sci Info. All rights reserved.

2/3,AB/10 (Item 1 from file: 144)

13865660 PASCAL No.: 99-0043484

Impact of M49, Mrp, Enn, and C5a peptidase proteins on colonization the mouse oral mucosa by *Streptococcus pyogenes*

YINDUO JI; SCHNITZLER N; DEMASTER E; CLEARY P
Department of Microbiology, University of Minnesota, Minneapolis, Minnesota, United States; Institute of Medical Microbiology and Nation Reference Laboratory for Streptococci, University Hospital, Aachen, Germany
Journal: Infection and immunity, 1998
, 66 (11) 5399-5405

Language: English

Resistance to phagocytosis is a hallmark of virulent *Streptococcus pyogenes* (group A streptococcus). Surface-bound C5a peptidase recruitment of phagocytes to the site of infection, and hyaluronic capsules and/or the M protein limit the uptake of streptococci. In study the relative impact of M and M-like proteins and the C5a peptidase the virulence of a serotype M49 strain was assessed. The capacity of isogenic strains with an insertion mutation in *emm49*; with a deletion mutation in *scpA49* (C5a peptidase gene); and with a deletion that removes all three M-like genes, *mrp49*, *emm49*, and *enn49*, to colonize mice and resist phagocytosis were compared. Experiments confirmed results obtained in an earlier study, which showed that the M49 protein was not required for in vitro resistance to phagocytosis, and also showed that the M protein is not required for colonization of mice. Failure to produce all three M proteins, M49, Mrp, and Enn49, significantly reduced the ability of streptococci to resist phagocytosis in vitro but did not significantly alter the persistence of streptococci on the oral mucosa. In experiments indicate that M SUP + streptococci are phagocytized by polymorphonuclear leukocytes that have been activated by phorbol-12-myristate 13-acetate or recombinant human C5a. This observation may explain the finding that expression of M49 protein is not essential for short-term colonization of the mouse oral mucosa.

Copyright (c) 1999 INIST-CNRS. All rights reserved.

Pascal (Dialog® File 144): (c) 2004 INIST/CNRS. All rights reserved.

2/3,AB/11 (Item 1 from file: 340)

Dialog Acc No: 10198304 IFI Acc No: 2002-0142009 IFI Acc No: 2002-00
Document Type: C
STREPTOCOCCAL C5A PEPTIDASE VACCINE; INFECTION THERAPY; ADMINISTERING
VACCINE

Inventors: Cleary Paul Patrick (US); Stafslie Deborah K (US)

Assignee: Minnesota, University of Regents

Assignee Code: 56024

Publication (No,Date), Applic (No,Date):

US 20020142009 20021003 US 2001870122 20010530

Publication Kind: A1

Continuation Pub(No), Applic(No,Date): UNKNOWN

WO

99US28826 19991203

Cont.-in-part Pub(No), Applic(No,Date): US 5846547

US

96589756 19960122

Priority Applic(No,Date): US 2001870122 20010530; WO 99US28826 1999

US 96589756 19960122

Abstract: Novel vaccines for use against beta -hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). disclosed is a method of protecting a susceptible mammal against beta -hemolytic Streptococcus colonization or infection by administering su vaccine. Enzymatically inactive SCP, and polynucleotides encoding thes proteins are further disclosed.

CLAIMS(R)/US Patent (Dialog® File 340): (c) 2004 IFI/CLAIMS(R). All rights reserved.

2/3,AB/12 (Item 2 from file: 340)

Dialog Acc No: 3647029 IFI Acc No: 0205872

Document Type: C

STREPTOCOCCAL C5A PEPTIDASE VACCINE

Inventors: Cleary Paul Patrick (US); Stafslie Deborah K (US)

Assignee: Minnesota, University of Regents

Assignee Code: 56024

Publication (No,Date), Applic (No,Date):

US 6355255 20020312 US 98206898 19981207

Publication Kind: B

Calculated Expiration: 20160122

Cont.-in-part Pub(No), Applic(No,Date): US 5846547

US

96589756 19960122

Priority Applic(No,Date): US 98206898 19981207; US 96589756 1996

Abstract: Novel vaccines for use against beta -hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). A disclosed is a method of protecting a susceptible mammal against beta -hemolytic Streptococcus colonization or infection by administering su vaccine. Enzymatically inactive SCP, and polynucleotides encoding the proteins are further disclosed.

CLAIMS(R)/US Patent (Dialog® File 340): (c) 2004 IFI/CLAIMS(R). All rights reserved.

2/3,AB/13 (Item 1 from file: 349)

00571114

STREPTOCOCCAL C5a PEPTIDASE VACCINE

VACCIN ANTI-STREPTOCOCCIQUE A BASE DE PEPTIDASE C5a

Patent Applicant/Assignee:

REGENTS OF THE UNIVERSITY OF MINNESOTA,

CLEARY Paul Patrick,

STAFSLIEN Deborah K,

Inventor(s):

CLEARY Paul Patrick,

STAFSLIEN Deborah K,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200034487 A1 20000615 (WO 0034487)

Application: WO 99US28826 19991203 (PCT/ WO US9928826)

Priority Application: US 98206898 19981207

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 17798

English Abstract

Novel vaccines for use against beta-hemolytic i(Streptococcus) colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against beta-hemolytic i(Streptococcus) colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.

French Abstract

La presente invention concerne des vaccins convenant contre la colonisation ou l'infection par le streptocoque beta-hemolytique. Ces vaccins contiennent une quantite immunogene d'une variante de la peptidase C5a streptococcique (SCP). L'invention concerne egalement un procede conferant a un mammifere sensible une protection contre la colonisation ou l'infection par le streptocoque beta-hemolytique, lequel procede consiste en une administration d'un tel vaccin. L'invention concerne en outre une peptidase C5a streptococcique enzymatiquement inactive ainsi que des polynucleotides codant les proteines de cette peptidase C5a streptococcique.

PCT FULLTEXT (Dialog® File 349): (c) 2004 WIPO/Univentio. All rights reserved.

2/3,AB/14 (Item 2 from file: 349)

00385265

STREPTOCOCCAL C5a PEPTIDASE VACCINE

VACCIN A BASE DE PEPTIDASE C5a DU STREPTOCOQUE

Patent Applicant/Assignee:

REGENTS OF THE UNIVERSITY OF MINNESOTA,

CLEARY Paul P,

Inventor(s):

CLEARY Paul P,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9726008 A1 19970724

Application: WO 97US1056 19970121 (PCT/ WO US9701056)

Priority Application: US 96589756 19960122

Designated States: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES
FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX
NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN KE LS MW SD
SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 17881

English Abstract

Novel vaccines for use against 'beta'-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of streptococcal C5a peptidase, or a fragment or mutant thereof. Also disclosed is a method of protecting a susceptible mammal against 'beta'-hemolytic Streptococcus colonization or infection by administering such a vaccine.

French Abstract

La presente invention concerne des vaccins contre la colonisation ou l'infection par Streptococcus 'beta'-hemolytique. Le vaccin contient une quantite immunogene de peptidase C5a du streptocoque, ou bien l'un de ses fragments ou l'un de ses mutants. L'invention concerne egalement un procede de protection d'un mammifere sensible contre la colonisation ou l'infection par Streptococcus 'beta'-hemolytique, et ce, par administration d'un tel vaccin.

PCT FULLTEXT (Dialog® File 349): (c) 2004 WIPO/Univentio. All rights reserved.

2/3,AB/15 (Item 1 from file: 399)

127160564 CA: 127(12)160564f PATENT

Complement C5a peptidase vaccines against .beta.-hemolytic Streptococcus

Inventor (Author): Cleary, Paul P.

Location: USA

Assignee: Regents of the University of Minnesota; Cleary, Paul P.

Patent: PCT International ; WO 9726008 A1 **Date:** 19970724

Application: WO 97US1056 (19970121) *US 589756 (19960122)

Pages: 76 pp.

CODEN: PIXXD2

Language: English

Class: A61K-039/09A

Designated Countries: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; HU; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; TJ; TM; TR; TT; UA; UG; US; UZ; VN; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

Designated Regional: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

CA SEARCH(R) (Dialog® File 399): (c) 2004 American Chemical Society. All rights reserved.

2/3,AB/16 (Item 1 from file: 654)

0005087253

Derwent Accession: 2000-423430

Streptococcal C5a peptidase vaccine

Inventor:Paul Cleary, INV

Deborah Stafslie, INV

Assignee: Regents of the University of Minnesota (02)

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 20020142009	A1	20021003	US 2001870122	20010530
Continuation	UNKNOWN			WO 99US28826	19991203
CIP	US 5846547			US 96589756	19960122
Priority				WO 99US28826	19991203
				US 96589756	19960122
				US 2001870122	20010530

Abstract:

Novel vaccines for use against [small beta, Greek]-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a pept (SCP). Also disclosed is a method of protecting a susceptible mammal against [small beta, Greek]-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SC and polynucleotides encoding these SCP proteins are further disclose

US Pat.Full. (Dialog® File 654): (c) Format only 2004 The Dialog Corp. All rights reserved.

2/3,AB/17 (Item 2 from file: 654)

4643471

Derwent Accession: 2000-423430

Utility

CERTIFICATE OF CORRECTION

C/ Streptococcal C5a peptidase vaccine

Inventor: Cleary, Paul Patrick, Shoreview, MN

Staflslien, Deborah K., Fridley, MN

Assignee: Regents of the University of Minnesota (02), Minneapolis, MN

Minnesota, University of Regents (Code: 56024)

Examiner: Smith, Lynette R. F. (Art Unit: 165)

Assistant Examiner: Hines, Jana A.

Law Firm: Schwegman, Lundberg, Woessner & Kluth, P.A.

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 6355255	A	20020312	US 98206898	19981207
CIP	US 5846547	A		US 96589756	19960122
Priority				US 98206898	19981207
				US 96589756	19960122

Abstract:

Novel vaccines for use against [beta]-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of streptococcal C5a peptidase (SCP). disclosed is a method of protecting a susceptible mammal against [beta]-hemolytic Streptococcus colonization or infection by administ such a vaccine. Enzymatically inactive SCP, and polynucleotides enco these SCP proteins are further disclosed.

Document type: C CERTIFICATE OF CORRECTION

US Pat.Full. (Dialog® File 654): (c) Format only 2004 The Dialog Corp. All rights reserved.

2/3,AB/18 (Item 3 from file: 654)

4550114

Derwent Accession: 1997-385115

Utility

C/ Streptococcal C5a peptidase vaccine; FOR USE

AGAINST BETA-HEMOLYTIC STREPTOCOCCUS COLONIZATION OR INFECTION; CONTAIN
IMMUNOGENIC AMOUNT OF STREPTOCOCCAL C5A PEPTIDASE, OR A FRAGMENT OR MUTANT
THEREOF.

Inventor: Cleary, Paul Patrick, Shoreview, MN

Assignee: Regents of the University of Minnesota (02), Minneapolis, MN
Minnesota, University of Regents (Code: 56024)

Examiner: Minnifield, Nita (Art Unit: 165)

Assistant Examiner: Baskar, Padma

Law Firm: Schwegman, Lundberg, Woessner & Kluth, P.A.

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 6270775	A	20010807	US 98206800	19981207
Division	US 5846547	A		US 96589756	19960122
Priority				US 98206800	19981207
				US 96589756	19960122

Abstract:

Novel vaccines for use against [beta]-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of streptococcal C5a peptidase, or a fragment or mutant thereof. Also disclosed is a method of protecting a susceptible mammal against [beta]-hemolytic Streptococcus colonization or infection by administering such a vaccine.

Document type: C

US Pat.Full. (Dialog® File 654): (c) Format only 2004 The Dialog Corp. All rights reserved.

2/3,AB/19 (Item 4 from file: 654)

4081438

Derwent Accession: 1997-385115

Utility

CERTIFICATE OF CORRECTION

C/ Streptococcal C5a peptidase vaccine

Inventor: Cleary, Paul Patrick, Shoreview, MN

Assignee: Regents of the University of Minnesota (02), Minneapolis, MN
Minnesota, University of Regents (Code: 56024)

Examiner: Loring, Susan A. (Art Unit: 161)

Law Firm: Schwegman, Lundberg, Woessner & Kluth, P.A.

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 5846547	A	19981208	US 96589756	19960122
Priority				US 96589756	19960122

Abstract:

Novel vaccines for use against [beta]-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of streptococcal C5a peptidase, or a fragment or mutant thereof. Also disclosed is a method of protecting a susceptible mammal against [beta]-hemolytic Streptococcus colonization or infection by administering such a vaccine.

Document type: C CERTIFICATE OF CORRECTION

US Pat.Full. (Dialog® File 654): (c) Format only 2004 The Dialog Corp. All rights reserved.

© 2004 Dialog, a Thomson business